ID   SNU-601
AC   CVCL_0101
SY   SNU601; NCI-SNU-601
DR   EFO; EFO_0006756
DR   ArrayExpress; E-MTAB-2706
DR   ArrayExpress; E-MTAB-2770
DR   BioSample; SAMN03473177
DR   BioSample; SAMN10988047
DR   cancercelllines; CVCL_0101
DR   Cell_Model_Passport; SIDM01445
DR   CGH-DB; 126-1
DR   CGH-DB; 9014-4
DR   Cosmic; 685585
DR   Cosmic; 848141
DR   Cosmic; 869513
DR   Cosmic; 921599
DR   Cosmic; 1090455
DR   Cosmic; 1294955
DR   Cosmic; 1528876
DR   Cosmic; 2484961
DR   Cosmic; 2646592
DR   Cosmic; 2807648
DR   DepMap; ACH-000736
DR   EGA; EGAS00001000610
DR   GEO; GSM888721
DR   GEO; GSM1374894
DR   IARC_TP53; 7420
DR   KCLB; 00601
DR   LiGeA; CCLE_780
DR   PharmacoDB; SNU601_1472_2019
DR   Progenetix; CVCL_0101
DR   Wikidata; Q54955227
RX   PubMed=9033653;
RX   PubMed=10812166;
RX   PubMed=15723654;
RX   PubMed=19956504;
RX   PubMed=22460905;
RX   PubMed=24807215;
RX   PubMed=25485619;
RX   PubMed=25877200;
RX   PubMed=25960936;
RX   PubMed=26589293;
RX   PubMed=29435981;
RX   PubMed=30894373;
RX   PubMed=31068700;
RX   PubMed=31395879;
RX   PubMed=32028591;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: Seoul National University (SNU) cell line collection.
CC   Part of: TCGA-110-CL cell line panel.
CC   Population: Korean.
CC   Doubling time: 29 hours (PubMed=29435981).
CC   HLA typing: A*11:01,26:01; B*15:01,40:01; C*04:01,15:02; DQB1*06:02,06:02 (PubMed=25960936).
CC   HLA typing: A*11:01,26:01; B*15:01,40:01; C*04:01,15:02; DQB1*06:02,06:02; DRB1*13:05,15:01 (PubMed=26589293).
CC   Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (PubMed=9033653; DepMap).
CC   Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu542Lys (c.1624G>A); ClinVar=VCV000031944; Zygosity=Heterozygous (DepMap).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Homozygous (PubMed=9033653; DepMap).
CC   Omics: Deep exome analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Genome ancestry: African=1.93%; Native American=0.43%; East Asian, North=63.23%; East Asian, South=33.73%; South Asian=0%; European, North=0%; European, South=0.68% (PubMed=30894373).
CC   Derived from site: Metastatic; Ascites; UBERON=UBERON_0007795.
ST   Source(s): KCLB; PubMed=25877200
ST   Amelogenin: X,Y
ST   CSF1PO: 10,11
ST   D13S317: 9,12
ST   D16S539: 12
ST   D18S51: 14
ST   D21S11: 29,30
ST   D3S1358: 16
ST   D5S818: 10
ST   D7S820: 9,11
ST   D8S1179: 13,14
ST   FGA: 23
ST   Penta D: 8,15
ST   Penta E: 11,18
ST   TH01: 7,9
ST   TPOX: 8,11
ST   vWA: 16,18
DI   NCIt; C5250; Gastric signet ring cell adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   34Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 30-01-24; Version: 35
//
RX   PubMed=9033653; DOI=10.1002/(SICI)1097-0215(19970207)70:4<443::AID-IJC12>3.0.CO;2-G;
RA   Park J.-G., Yang H.-K., Kim W.-H., Chung J.-K., Kang M.-S., Lee J.-H.,
RA   Oh J.H., Park H.-S., Yeo K.-S., Kang S.H., Song S.-Y., Kang Y.K.,
RA   Bang Y.-J., Kim Y.I., Kim J.-P.;
RT   "Establishment and characterization of human gastric carcinoma cell
RT   lines.";
RL   Int. J. Cancer 70:443-449(1997).
//
RX   PubMed=10812166; DOI=10.1016/S0165-4608(99)00217-4;
RA   Chun Y.-H., Kil J.-I., Suh Y.-S., Kim S.-H., Kim H., Park S.-H.;
RT   "Characterization of chromosomal aberrations in human gastric
RT   carcinoma cell lines using chromosome painting.";
RL   Cancer Genet. Cytogenet. 119:18-25(2000).
//
RX   PubMed=15723654; DOI=10.1111/j.1349-7006.2005.00016.x;
RA   Takada H., Imoto I., Tsuda H., Sonoda I., Ichikura T., Mochizuki H.,
RA   Okanoue T., Inazawa J.;
RT   "Screening of DNA copy-number aberrations in gastric cancer cell lines
RT   by array-based comparative genomic hybridization.";
RL   Cancer Sci. 96:100-110(2005).
//
RX   PubMed=19956504; DOI=10.4143/crt.2005.37.1.1;
RA   Ku J.-L., Park J.-G.;
RT   "Biology of SNU cell lines.";
RL   Cancer Res. Treat. 37:1-19(2005).
//
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=24807215; DOI=10.1038/ncomms4830;
RA   Liu J.-F., McCleland M.L., Stawiski E.W., Gnad F., Mayba O., Haverty P.M.,
RA   Durinck S., Chen Y.-J., Klijn C., Jhunjhunwala S., Lawrence M.,
RA   Liu H.-B., Wan Y.-N., Chopra V.S., Yaylaoglu M.B., Yuan W.-L., Ha C.,
RA   Gilbert H.N., Reeder J., Pau G., Stinson J., Stern H.M., Manning G.,
RA   Wu T.D., Neve R.M., de Sauvage F.J., Modrusan Z., Seshagiri S.,
RA   Firestein R., Zhang Z.-M.;
RT   "Integrated exome and transcriptome sequencing reveals ZAK isoform
RT   usage in gastric cancer.";
RL   Nat. Commun. 5:3830.1-3830.8(2014).
//
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S.,
RA   Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G.,
RA   Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J.,
RA   Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L.,
RA   Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J.,
RA   Settleman J., Seshagiri S., Zhang Z.-M.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
//
RX   PubMed=25877200; DOI=10.1038/nature14397;
RA   Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M.,
RA   Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S.,
RA   Neve R.M.;
RT   "A resource for cell line authentication, annotation and quality
RT   control.";
RL   Nature 520:307-311(2015).
//
RX   PubMed=25960936; DOI=10.4161/21624011.2014.954893;
RA   Boegel S., Lower M., Bukur T., Sahin U., Castle J.C.;
RT   "A catalog of HLA type, HLA expression, and neo-epitope candidates in
RT   human cancer cell lines.";
RL   OncoImmunology 3:e954893.1-e954893.12(2014).
//
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
//
RX   PubMed=29435981; DOI=10.1002/ijc.31304;
RA   Kim H.J., Kang S.K., Kwon W.S., Kim T.S., Jeong I., Jeung H.-C.,
RA   Kragh M., Horak I.D., Chung H.C., Rha S.Y.;
RT   "Forty-nine gastric cancer cell lines with integrative genomic
RT   profiling for development of c-MET inhibitor.";
RL   Int. J. Cancer 143:151-159(2018).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//
RX   PubMed=31395879; DOI=10.1038/s41467-019-11415-2;
RA   Yu K., Chen B., Aran D., Charalel J., Yau C., Wolf D.M.,
RA   van 't Veer L.J., Butte A.J., Goldstein T., Sirota M.;
RT   "Comprehensive transcriptomic analysis of cell lines as models of
RT   primary tumors across 22 tumor types.";
RL   Nat. Commun. 10:3574.1-3574.11(2019).
//
RX   PubMed=32028591; DOI=10.3390/cancers12020334;
RA   Kim J.W., Min A., Im S.-A., Jang H., Kim Y.J., Kim H.-J., Lee K.-H.,
RA   Kim T.-Y., Lee K.W., Oh D.-Y., Kim J.-H., Bang Y.-J.;
RT   "TDP1 and TOP1 modulation in olaparib-resistant cancer determines the
RT   efficacy of subsequent chemotherapy.";
RL   Cancers (Basel) 12:334.1-334.17(2020).
//